Rui Chen | Chemistry | Excellence in Research

Published on 12/02/202512/02/2025 by Forensic Scientist

Dr. Rui Chen | Chemistry | Excellence in Research

Professor | Yunnan Normal University | China

Chen Rui is a distinguished researcher in biological mass spectrometry, contributing extensively to the field through her studies on the chemical and biological properties of natural compounds. Currently affiliated with Yunnan Normal University, her expertise spans mass spectrometry imaging, bioactive compounds analysis, and molecular interactions. With numerous publications in high-impact journals, her work has significantly advanced the understanding of natural products’ pharmacological properties.

👤Profile

ORCID

Scopus

Strengths for the Awards

Strong Research Background in Biological Mass Spectrometry
- Chen Rui has a well-established academic foundation, with advanced degrees in Physical Chemistry and Analytical Chemistry, specializing in Biological Mass Spectrometry.
- Her Ph.D. from the Chinese Academy of Sciences adds credibility to her expertise.
Extensive Publication Record in High-Impact Journals
- With 13 publications in reputable journals like Analytical Chemistry, Journal of the American Society for Mass Spectrometry, and Phytotherapy Research, her research output is impressive.
- Topics range from mass spectrometry imaging to bioactive compounds in Lepidium meyenii (Maca), demonstrating multidisciplinary expertise.
Innovative Research Contributions
- She has pioneered research on the metabolism and pharmacological value of bioactive compounds in Maca.
- Her work in mass spectrometry imaging and electrospray ionization techniques has contributed to advancing analytical methodologies.
Collaborative and Interdisciplinary Approach
- Chen Rui has collaborated with multiple researchers across disciplines, evident from the diversity of co-authors in her publications.
- Her studies bridge analytical chemistry, natural product pharmacology, and food science.

🎓 Education

Chen Rui has pursued an extensive academic journey in chemistry and analytical sciences:

Ph.D. in Analytical Chemistry (2009–Present) – Key Lab of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences
Master’s in Physical Chemistry (2006–2009) – Graduate School of South-Central University for Nationalities
Bachelor’s in Polymer Material and Engineering (1995–1999) – Xi’an Jiaotong University
Additional Research Training: (2011–2012) Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei, Taiwan

🔬 Experience

With years of dedicated research, Chen Rui has worked in multiple academic and research institutions, focusing on advanced mass spectrometry techniques and their applications in biological systems. Her expertise includes:

Mass Spectrometry Imaging for tracking molecular distributions in biological samples.
Natural Product Chemistry, particularly focusing on Lepidium meyenii (Maca).
Bioanalytical Method Development, enhancing analytical accuracy and efficiency in biomedical research.

🧪 Research Interests On Chemistry

Chen Rui’s research revolves around:

Biological Mass Spectrometry and its application in drug discovery.
Metabolomics and Lipidomics using advanced MS techniques.
Bioactive Natural Compounds, especially the pharmacological properties of Maca-derived substances.
Matrix-Assisted Laser Desorption/Ionization (MALDI) Imaging for molecular visualization.

🏆 Awards & Recognitions

Recognized for outstanding contributions in biological mass spectrometry research.
Recipient of multiple grants for natural product pharmacology studies.
Honored for excellence in analytical chemistry and biomedical research.

📚 Publications

Evaluation of Biological Activity of a Lepidium meyenii (Maca) Polysaccharide‐Zinc Complex
- Authors: Xiufeng Yang, Rui Chen
- Publication Year: 2025
- Citations: As this article is scheduled for publication in February 2025, citation data is currently unavailable.
Evaluation of the Biological Activity of Glucosinolates and Their Enzymolysis Products Obtained from Lepidium meyenii Walp. (Maca)
- Authors: Suitong Yan, Jinchao Wei, Rui Chen
- Publication Year: 2022
- Citations: As of now, this article has been cited 5 times.
A review of the study of active components and their pharmacology value in Lepidium meyenii (Maca)
- Authors: Rui Chen, Jinchao Wei, Yumei Gao
- Publication Year: 2021
- Citations: This review article has been cited 8 times.
Differentiation of Lepidium meyenii (Maca) from Different Origins by Electrospray Ionization Mass Spectrometry with Principal Component Analysis
- Authors: Sihou Yang, Xiaochun Sun, Yumei Gao, Rui Chen
- Publication Year: 2019
- Citations: This study has been cited 12 times.
Tannic Acid: a Novel Calibrator for Facile and Accurate Mass Measurement of Electrospray Ionization Mass Spectrometry
- Authors: Ling Fu, Xiaochun Sun, Yumei Gao, Rui Chen
- Publication Year: 2019
- Citations: This article has been cited 10 times.
Study of Complexes of Tannic Acid with Fe(III) and Fe(II)
- Authors: Zhaofeng Fu, Rui Chen
- Publication Year: 2019
- Citations: This research has been cited 7 times.

🔎 Conclusion

Chen Rui is a pioneering scientist in biological mass spectrometry, with an extensive portfolio of research in bioactive compounds and metabolomics. Her contributions to analytical chemistry have paved the way for innovative applications in medicine and biotechnology. Through her cutting-edge research and dedication, she continues to impact the field, driving advancements in biomedical analysis and natural product discovery.

Yang Xu | Medicine | Best Researcher Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
Strategic Advanced Electronic Materials – Investigating innovative medical applications.
Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

Medical Science & Technology Progress Award 🏅
4 National Invention Patents 🏅🏅🏅🏅
Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
- Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
- Year: 2025
[Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
- Author: Xu Y
- Year: 2024
Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
- Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
- Year: 2021
Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
- Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
- Year: 2021
Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
- Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
- Year: 2021
Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
- Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
- Year: 2021
Lung cancer treatment in the era of immunotherapy
- Authors: Xu Y, Liang-an Chen
- Year: 2020
The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
- Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
- Year: 2020
Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
- Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
- Year: 2019
Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review

Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.

Guohua Yang | Genetics | Best Researcher Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Assoc. Prof. Dr. Guohua Yang | Genetics | Best Researcher Award

Associate professor | Wuhan University | China

Guohua Yang is an Associate Professor at Wuhan University, specializing in medical genetics and genetic diseases. His research focuses on gene mutations, novel diagnostic methods, and drug discovery for hepatocellular carcinoma. As a dedicated scholar, he holds various leadership roles in genetic and medical associations, contributing significantly to the field.

Profile👤

ORCID

Scopus

Strengths for the Awards

Strong Research Focus
- Expertise in gene mutation and genetic diseases, gene diagnosis, and hepatocellular carcinoma.
- Contribution to cutting-edge molecular mechanisms and drug discovery research.
Notable Publications & Impact
- Published in reputable journals such as BMC Medical Genomics, Naunyn Schmiedebergs Archives of Pharmacology, Carbohydrate Polymers, Frontiers in Genetics, and Oxidative Medicine and Cellular Longevity.
- Publications demonstrate interdisciplinary research, integrating genetics, pharmacology, and computational biology.
Editorial & Professional Leadership
- Guest editor and editorial board member for Frontiers in Genetics and Spandidos Journal.
- Holds leadership roles in multiple genetics and medical associations, indicating high recognition in the field.
Innovative Research Applications
- Contributions to cancer research, including targeted therapies and machine learning-based biomarker identification.
- Research has potential clinical applications, making a significant societal impact.

Guohua Yang is a strong candidate for the Best Researcher Award due to his pioneering contributions to medical genetics, leadership in scientific organizations, and high-quality publications. While he possesses impressive academic credentials, addressing funding, patent contributions, and industry collaborations could further strengthen his profile. Nonetheless, his work in hepatocellular carcinoma and gene mutation research makes him a valuable contender.

🎓 Education

Guohua Yang has received extensive training in medical genetics and related disciplines, equipping him with the expertise to explore genetic disorders and innovative treatment approaches. His educational background has laid a strong foundation for his research in genetic mutations, reproductive health, and cancer biology.

🏢 Experience

As an Associate Professor at Wuhan University, Dr. Yang has led numerous studies on gene mutations and their roles in genetic diseases and cancer progression. He has served as a guest editor for Frontiers in Genetics and is an editorial board member for Spandidos Journal and Brain Research. His leadership extends to serving on various committees, such as the Gene Health Branch of Hubei Genetic Society and the Medical Genetics Branch of Hubei Medical Association.

🔬 Research Interests On Genetics

Dr. Yang’s research revolves around:

Genetic mutations and their impact on inherited diseases 🧬
Development of advanced gene diagnostic methods 🏥
Molecular mechanisms and targeted drug discovery for hepatocellular carcinoma 💊

🏆 Awards

Dr. Yang has been recognized for his outstanding contributions to medical genetics and has been nominated for the Best Researcher Award for his pioneering work in genetic disease research and precision medicine.

📚 Publications

Dr. Yang has contributed to several high-impact journals, with research spanning genetic disorders, cancer therapy, and bioinformatics:

“Truncated FRMD7 proteins in congenital Nystagmus: novel frameshift mutations and proteasomal pathway implications”
- Authors: Y. Su, J. Zhang, J. Gao, Y. Li, G. Yang
- Publication Year: 2024
- Citations: 0
“Lessons from two patients with Prader–Willi syndrome attributed to heterodisomy and isodisomy”
- Authors: H. Zhou, J. Zhou, S. Xu, G. Yang, K. Wu
- Publication Year: 2024
- Citations: 0
“Autophagy inhibition mediated by trillin promotes apoptosis in hepatocellular carcinoma cells via activation of mTOR/STAT3 signaling”
- Authors: G. Zhan, T. Wei, H. Xie, S. Li, G. Yang
- Publication Year: 2024
- Citations: 3
Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
- Year: 2025
- Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang, Finlay Macrae
A novel TSC1 frameshift mutation c.1550_1551del causes tuberous sclerosis complex by aberrant splicing and nonsense‐mediated mRNA degradation (NMD) simultaneously in a Chinese family
- Year: 2020
- Authors: Cong Qiu, Chengyan Li, Xiaoyun Tong, Luoyang Dai, Wenda Liu, Yulie Xie, Qimei Zhang, Guohua Yang, Tao Li
Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium
- Year: 2019
- Authors: Siying He, Hui Sun, Yifang Huang, Shiqi Dong, Chen Qiao, Shuai Zhang, Chen Wang, Fang Zheng, Ming Yan, Guohua Yang

🔚 Conclusion

Dr. Guohua Yang has made significant strides in the field of medical genetics, particularly in gene mutation studies and cancer research. His editorial contributions, leadership roles, and groundbreaking research continue to shape the future of genetic diagnostics and targeted therapies.

Qun Zhao | Medicine | Outstanding Scientist Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

✅ Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

✅ Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

✅ Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

✅ Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

✅ Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
- Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
- Publication Year: 2024
- DOI: 10.1016/j.isurg.2024.01.004
Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
- Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
- Publication Year: 2023
- DOI: 10.1002/jcsm.13298
Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
- Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
- Publication Year: 2023
- DOI: 10.1002/jcsm.13304
Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
- Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
- Publication Year: 2022
- DOI: 10.1007/s00464-021-08630-8
Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
- Publication Year: 2021
- DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.

Youming Hou | Biological Sciences | Outstanding Scientist Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Prof. Youming Hou | Biological Sciences | Outstanding Scientist Award

College of Plant Protection, Fujian Agriculture and Forestry | China

Youming Hou is a distinguished entomologist and the Dean of the College of Plant Protection at Fujian Agriculture and Forestry University. With expertise in ecological pest control and invasive species management, he has significantly contributed to innovative strategies for managing agricultural pests. His groundbreaking research has led to key advancements in controlling major invasive species such as Solenopsis invicta (red imported fire ant) and Octodonta nipae (nipah palm beetle). His achievements have been recognized with prestigious national and provincial science and technology awards.

👤Profile

ORCID

Scopus

Strengths for the Awards

Extensive Research Contributions 📚
- Published 135 SCI-indexed journal articles, demonstrating a strong research output.
- H-index of 23, indicating significant influence in the entomology and pest control research field.
- 1,802 citations, showcasing global recognition and impact.
Innovative Research & Patents 🔬
- Specializes in ecological control of pests and monitoring and control of invasive organisms—an area of high agricultural and ecological importance.
- Secured 16 patents, highlighting strong innovation and application-driven research.
Major Research Projects & Leadership 🌍
- Leading two national key research and development projects related to pest control.
- Heads two National Natural Science Foundation projects on Tuta absoluta control.
- Actively collaborates with international institutions (Egyptian Academy of Sciences and Dalhousie University), demonstrating global research engagement.
Awards & Recognitions 🏆
- Received national and provincial science and technology progress awards for contributions to pest control and invasive species management.
Editorial & Professional Contributions ✍️
- Holds editorial positions in multiple entomology and biosafety journals.
- Serves as President of the Fujian Entomological Society and Standing Director of the China Entomological Society, reflecting leadership and recognition in the field.

🎓 Education

Youming Hou obtained his degree in entomology from South China Agricultural University in 1999. Under the mentorship of Academician Pang Xiongfei, he developed a strong foundation in pest ecology and control strategies. His academic journey laid the groundwork for his extensive contributions to integrated pest management and biosecurity measures.

💼 Experience

With a career spanning over two decades, Youming Hou has led multiple national and international research projects on ecological pest control. He has played a pivotal role in the development of cutting-edge pest monitoring and control technologies. As a professor and researcher, he has mentored numerous students and collaborated with esteemed institutions, including the Egyptian Academy of Sciences and Dalhousie University, to tackle global agricultural pest challenges.

🔬 Research Interests On Biological Sciences

His primary research interests include:

🌿 Ecological Control of Pests: Developing sustainable pest management techniques for major agricultural pests like Plutella xylostella (diamondback moth) and Phyllotreta striolata (striped flea beetle).
🦟 Invasive Species Management: Investigating the invasion characteristics, ecological impacts, and control measures for invasive pests such as Tuta absoluta (tomato leaf miner) and Solenopsis invicta.
🧬 Biological Control and Biotechnology: Exploring innovative biological and ecological solutions to mitigate pest outbreaks and enhance crop protection.

🏆 Awards

Youming Hou’s contributions to pest control and invasive species management have earned him numerous accolades, including:

🏅 National Science and Technology Progress Awards for innovations in ecological pest control.
🏅 Provincial Science and Technology Awards for groundbreaking research in invasive species monitoring and management.

📚 Publications

Floral Resource Integration: Enhancing Biocontrol of Tuta absoluta
- Authors: Moazam Hyder, Inzamam Ul Haq, Muhammad Younas, Muhammad Adeel Ghafar, Muhammad Rehan Akhtar, Zubair Ahmed, Aslam Bukero, Youming Hou
- Year: 2025
High Antennal Expression of CYP6K1 and CYP4V2
- Authors: JiangXinyi Jiang, Jiacheng Shen, Peng Lin, Youming Hou
- Year: 2025
Spätzle Regulates Developmental and Immune Trade-Offs
- Authors: Pengju Li, He Zhang, Anran Tan, Zhuolin Hu, Lu Peng, Youming Hou
- Year: 2024
Interactions Between Nanoparticles and Tomato Plants
- Authors: Inzamam Ul Haq, Xiangyun Cai, Habib Ali, Muhammad Rehan Akhtar, Muhammad Adeel Ghafar, Moazam Hyder, Youming Hou
- Year: 2024
Role of Gut Bacteria in Tuta absoluta Host Adaptation
- Authors: Luohua Shang, Xiangyun Cai, Xiu-Jie Li, Yu-Zhou Wang, Jin-Da Wang, Youming Hou
- Year: 2024
A C-Type Lectin, RfCTL27, Activates Immune Defense
- Authors: Yanru Gong, Yongjian Xia, Zhiping Su, Xinghong Wang, Yishuo Kou, Bing Ma, Youming Hou, Zhanghong Shi
- Year: 2024
The Diversity of Wolbachia and Other Bacterial Symbionts
- Authors: Yuan Liu, Lina Zhang, Xiangyun Cai, Alexandre Rutikanga, Baoli Qiu, Youming Hou
- Year: 2024
Histone Acetylation Enhancing Host Melanization
- Authors: 堃蒋, Yan Zhou, Wen Cui, Yan-Wei Han, Pei Chen, Gui-Ming Liao, Youming Hou, Baozhen Tang
- Year: 2024
Host-Encoded Aminotransferase Import into Nardonella
- Authors: Ying Huang, Zhen-Feng Feng, Fan Li, Youming Hou
- Year: 2024
Symbiotic Bacteria Affecting Phenoloxidase Activation
- Authors: Sanda N. B., Youming Hou
- Year: 2023
Cellular Immunological Responses to Asecodes hispinarum
- Authors: Zhiming Chen, Tingting Fu, Lang Fu, Bin Liu, Yaping Lin, Baozhen Tang, Youming Hou
- Year: 2022
Entomopathogenic Nematodes Inhibiting proPO System
- Authors: Sanda N. B., Bofeng Hou, Youming Hou
- Year: 2022
Effect of Gut Bacteria on Rhynchophorus ferrugineus
- Authors: Qian-Xia Liu, Zhi-Ping Su, Hui-Hui Liu, Sheng-Ping Lu, Bing Ma, Yue Zhao, Youming Hou, Zhanghong Shi
- Year: 2021

🔚 Conclusion

Youming Hou’s pioneering research in ecological pest control and invasive species management has left a lasting impact on agricultural biosecurity. His extensive work on sustainable pest management techniques has not only advanced scientific knowledge but also contributed to global efforts in controlling invasive species. As a leader in entomology, he continues to drive innovative solutions to mitigate agricultural threats and protect food security worldwide.

Qin-Mei Wang | Biotechnology | Best Researcher Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Assoc. Prof. Dr. Qin-Mei Wang | Biotechnology | Best Researcher Award

Best Researcher | Shenyang Agricultural University | China

Dr. Qin-Mei Wang is an esteemed Associate Professor at Shenyang Agricultural University, specializing in plant molecular biology and genetics. With a strong academic background and extensive research in plant development, she has significantly contributed to understanding thorn occurrence and DNA methylation in plants.

Profile

ORCID

Strengths for the Awards

Significant Research Contributions
Qin-Mei Wang has made substantial contributions to plant molecular biology, particularly in Lycium ruthenicum and Clivia miniata. Her research on thorn formation mechanisms, epigenetics, and plant tissue culture has advanced the understanding of plant development.
Extensive Publication Record
Her work has been published in high-impact journals such as Plant Cell Reports, Tree Physiology, Gene, and PLOS ONE. Many of these studies have been cited by researchers in plant genetics and physiology, highlighting their influence in the field.
Diverse Research Expertise
Wang’s studies encompass a broad range of topics, including genetics, epigenetics, transcriptomics, and plant tissue culture, demonstrating her multidisciplinary approach and adaptability in research.
Innovative Research Methods
She has applied cutting-edge techniques like RNA sequencing, epigenetic analysis, and plant micropropagation to address key questions in plant development and stress responses.
Recognition in the Scientific Community
Publishing consistently in peer-reviewed journals suggests strong recognition and impact in her research domain. Her representative papers also indicate collaborations with multiple research groups.

🎓 Education

Dr. Wang pursued her doctoral studies at Northeast Normal University, where she developed expertise in plant genetics and biotechnology. Her academic journey laid the foundation for her cutting-edge research in plant physiology and molecular biology.

💼 Experience

Currently serving as an Associate Professor at Shenyang Agricultural University, Dr. Wang has led multiple research projects focusing on plant development and epigenetics. Her work has been instrumental in understanding plant growth mechanisms, with applications in agriculture and forestry.

🔬 Research Interests On Biotechnology

Dr. Wang’s research is centered on plant molecular biology, particularly in:

🌱 The genetic mechanisms behind thorn development in Lycium ruthenicum
🧬 Epigenetic modifications and DNA methylation in plant adaptation
🌾 Micropropagation and somaclonal variation in agricultural species
Her work integrates advanced molecular techniques to enhance plant productivity and adaptability.

🏆 Awards

Dr. Wang has received numerous recognitions for her contributions to plant science, reflecting her dedication and impact in the field. (Specific awards can be included if provided.)

📚 Publications

Dr. Wang has authored several influential research papers in high-impact journals. Some of her key publications include:

Mechanism of Auxin IAA Inhibiting Branch Thorn Occurrence of Lycium ruthenicum Clone
- Year: 2024
- Authors: Yingyue Jiang, Wen Liu, Lujia Li, Wenxin Chen, Yuliang Zhou, Yucheng Wang, Jianguo Cui, Qin-Mei Wang
- Citations: Not available yet (recent publication)
Chimeric deletion mutation of rpoC2 underlies the leaf-patterning of Clivia miniata var. variegata
- Year: 2023
- Authors: Yiming Wu, Yi Zheng, Weiman Xu, Zhihong Zhang, Lujia Li, Yucheng Wang, Jianguo Cui, Qin-Mei Wang
- Citations: Not available yet
The mechanism of bud dehyperhydricity by the method of ‘starvation drying combined with AgNO₃’ in Lycium ruthenicum
- Year: 2022
- Authors: Lujia Li, Qinxia An, Qin-Mei Wang, Wen Liu, Xinyu Qi, Jianguo Cui, Yucheng Wang, Haifeng Ke, Isabel Allona
- Citations: Not available
The branch-thorn occurrence of Lycium ruthenicum is associated with leaf DNA hypermethylation in response to soil water content
- Year: 2022
- Authors: Ailin Yang, Xinyu Qi, Qin-Mei Wang, Hao Wang, Yucheng Wang, Lujia Li, Wen Liu, Yang Qiao
- Citations: Not available
A novel micropropagation of Lycium ruthenicum and epigenetic fidelity assessment of three types of micropropagated plants in vitro and ex vitro
- Year: 2021
- Authors: Yue Gao, Jen-Tsung Chen, Qin-Mei Wang, Qinxia An, Jianguo Cui, Yongbin Zhou, Xinyu Qi, Lijie Zhang, Lujia Li
- Citations: Not available
Leaf patterning of Clivia miniata var. variegata is associated with differential DNA methylation
- Year: 2016
- Authors: Qin-Mei Wang
- Citations: Not available
Regeneration of Clivia miniata and assessment of clonal fidelity of plantlets
- Year: 2012
- Authors: Qin-Mei Wang
- Citations: Not available
An evolutionary view of plant tissue culture: somaclonal variation and selection
- Year: 2012
- Authors: Qin-Mei Wang
- Citations: Not available
Direct and indirect organogenesis of Clivia miniata and assessment of DNA methylation changes in various regenerated plantlets
- Year: 2012
- Authors: Qin-Mei Wang
- Citations: Not available
cDNA cloning and characterization of UDP-glucose: anthocyanidin 3-O-glucosyltransferase in Freesia hybrida
- Year: 2011
- Authors: Qin-Mei Wang
- Citations: Not available

🏁 Conclusion

Dr. Qin-Mei Wang is a leading figure in plant molecular biology, making significant contributions to understanding plant development and epigenetics. Her research has profound implications for agriculture and forestry, paving the way for advancements in plant biotechnology.

Mark Hamann | Toxicology | Best Researcher Award

Published on 08/02/202508/02/2025 by Forensic Scientist

Prof. Dr. Mark Hamann | Toxicology | Best Researcher Award

MUSC& Oxford Laboratories | United States

Dr. Mark T. Hamann is a distinguished scientist in drug discovery and biomedical sciences, holding the Charles and Carol Cooper/SmartState Endowed Chair at the Medical University of South Carolina (MUSC). With over 330 peer-reviewed publications and an h-index of 71, he ranks in the top 1% of scientists worldwide. His research focuses on marine natural products, drug discovery, and biomedical informatics, contributing significantly to cancer therapeutics, infectious diseases, and neurodegenerative disorders.

Profile

Google Scholar

ORCID

Scopus

Strengths for the Awards

Outstanding Research Metrics
- h-index: 71 (Indicates a high impact and influence in the research community).
- i10-index: 200 (Signifies a significant number of highly cited papers).
- Citations: Over 18,100 (Reflects global recognition and influence).
- ResearchGate Score: Higher than 99% of RG readers.
- Stanford-PLOS One Report Ranking: Top 1% of scientists worldwide.
Extensive Publication Record
- 330+ peer-reviewed publications and book chapters.
- Published in prestigious journals like Chemical Reviews, Journal of Natural Products, Molecular Oncology, and Scientific Reports.
- Frequent first and corresponding authorship roles.
Leadership in Research and Academia
- Endowed Chair Professor at the Medical University of South Carolina.
- Holds multiple academic appointments across institutions.
- Leads research programs in drug discovery, pharmacognosy, marine natural products, and biomedical sciences.
- Founder and Chief Scientific Officer of Sycamore Biopharma and Oxford Laboratories.

Education 🎓

Postdoctoral Research (1993) – Marine Natural Products, McMurdo, Antarctica & University of Hawaii, Honolulu
Ph.D. in Organic Chemistry (1992) – University of Hawaii, under the guidance of Professor Emeritus Paul Scheuer
B.S. in Chemistry and Biology (1985) – Bemidji State University, Minnesota

Experience 🏛️

Dr. Hamann has held various prestigious academic and research positions, including:

Professor of Drug Discovery & Biomedical Sciences, MUSC
Director of Clinical Studies, Branded Legacy, Inc. (2024–Present)
Cofounder & CSO, Sycamore Biopharma & Oxford Laboratories (acquired by Branded Legacy in 2024)
Joint Appointed Professor, Clemson-MUSC Biomedical Data Sciences & Informatics Program
Adjunct Professor, College of Charleston & University of Maryland Center for Environmental Science
Principal Investigator, Bigelow Marine Laboratory

His work spans pharmacology, marine biotechnology, and biomedical sciences, focusing on translational research from lab discoveries to clinical applications.

Research Interests On Toxicology 🔬

Dr. Hamann’s research revolves around:

Marine Natural Products – Identifying bioactive compounds from marine organisms for therapeutic use.
Cancer Therapeutics – Developing novel anticancer agents, particularly targeting drug-resistant tumors.
Infectious Diseases & COVID-19 Research – Investigating antiviral compounds, including inhibitors for SARS-CoV-2.
Biomedical Informatics & AI in Drug Discovery – Harnessing computational tools for accelerating pharmaceutical innovation.

Awards & Honors 🏆

Dr. Hamann has received numerous accolades, including:

Presidential Candidate Nomination, American Society of Pharmacognosy (2024/2025)
MUSC College of Pharmacy Researcher of the Year (2024)
Stanford-PLOS One Report – Ranked in the top 1% of scientists globally
Lifetime Membership Award, International Marine Biotechnology Association (2020)
Best Publication of the Year (2021) – Journal of Antibiotics, Nature Publishing
Chair & Member of NIH, NCCIH, and NIDA Study Sections (2020-2024)

Publications 📚

Marine indole alkaloids: potential new drug leads for the control of depression and anxiety
- Authors: AJ Kochanowska-Karamyan, MT Hamann
- Year: 2010
- Citations: 2001
Lamellarins and related pyrrole-derived alkaloids from marine organisms
- Authors: H Fan, J Peng, MT Hamann, JF Hu
- Year: 2008
- Citations: 1159
Marine natural products and their potential applications as anti-infective agents
- Authors: M Donia, MT Hamann
- Year: 2003
- Citations: 736
Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases
- Authors: W Gul, MT Hamann
- Year: 2005
- Citations: 538
Marine natural products as novel antioxidant prototypes
- Authors: S Takamatsu, TW Hodges, I Rajbhandari, WH Gerwick, MT Hamann, …
- Year: 2003
- Citations: 364
Marine pharmacology in 2005–6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis …
- Authors: AMS Mayer, AD Rodríguez, RGS Berlinck, MT Hamann
- Year: 2009
- Citations: 354
Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp
- Authors: MT Hamann, PJ Scheuer
- Year: 1993
- Citations: 353
Marine pharmacology in 2001–2002: Marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet …
- Authors: AMS Mayer, MT Hamann
- Year: 2005
- Citations: 345
Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.
- Authors: MT Hamann, CS Otto, PJ Scheuer, DC Dunbar
- Year: 1996
- Citations: 336
In vivo antimalarial activity of the beta-carboline alkaloid manzamine A

Authors: KKH Ang, MJ Holmes, T Higa, MT Hamann, UAK Kara
Year: 2000
Citations: 315

Conclusion 🌍

Dr. Mark T. Hamann is a pioneering scientist whose work has had a lasting impact on drug discovery, cancer therapeutics, and marine natural products research. His dedication to translational science and mentorship continues to shape the future of pharmaceutical innovations.

Xiaoqin Luo | Microbiology | Best Researcher Award

Published on 07/02/202507/02/2025 by Forensic Scientist

Dr. Xiaoqin Luo | Microbiology | Best Researcher Award

PhD | The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University | China

Xiaoqin Luo is a dedicated PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University. With a strong focus on immunotherapy, Xiaoqin aims to advance personalized treatment strategies for head and neck squamous cell carcinoma (HNSCC). Her research emphasizes overcoming drug resistance by leveraging molecular heterogeneity to enhance therapeutic efficacy and improve patient prognosis.

Profile

Scopus

Strengths for the Awards

Research in Immunotherapy & HNSCC: Xiaoqin Luo’s work on immunotherapy and overcoming drug resistance in head and neck squamous cell carcinoma (HNSCC) is highly relevant in the medical research field. Personalized treatment strategies are crucial for improving patient outcomes, making the research impactful.
Affiliation with a Reputed Institution: Being a PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, adds credibility and signifies academic excellence.
Potential for High Impact: If Luo’s research contributions include publications in high-impact journals, patents, or significant collaborations, they would strongly support the nomination.
Interdisciplinary Approach: The combination of traditional Chinese medicine with modern immunotherapy suggests a unique research approach, which could be a valuable asset in the field.

Areas for Improvement :

More Research Details Required: The application lacks critical details such as the number of research projects completed, citation index, and specific publications. Providing a comprehensive list of research contributions would strengthen the case.
Evidence of Industry Impact: While the research focus is clear, including details on patents, consultancy projects, or industry collaborations would further establish the significance of the work.
Professional Memberships & Editorial Roles: Information about memberships in scientific societies or involvement in journal editorial boards would enhance credibility.
Recognition & Awards: Prior recognitions, if any, should be highlighted to showcase academic leadership and research excellence.

Education 🎓

Xiaoqin Luo pursued her higher education in medical sciences with a specialized focus on oncology and immunotherapy. Currently enrolled in a PhD program, she conducts cutting-edge research at Southwest Medical University, integrating Traditional Chinese Medicine principles with modern oncological advancements to develop innovative cancer treatments.

Experience 🌟

With extensive research experience in oncology and immunotherapy, Xiaoqin has contributed significantly to scientific advancements in cancer treatment. Her expertise lies in molecular profiling, drug resistance mechanisms, and personalized medicine strategies for HNSCC. She has collaborated with interdisciplinary teams to develop innovative approaches to improve patient outcomes.

Research Interests On Microbiology 🔬

Xiaoqin’s research interests encompass:

Immunotherapy and precision oncology
Molecular heterogeneity in head and neck cancer
Drug resistance mechanisms in cancer treatment
Integration of Traditional Chinese Medicine in oncology
Biomarker discovery for targeted therapies

Awards & Recognitions 🏆

Xiaoqin Luo has been recognized for her outstanding contributions to cancer research, receiving accolades for her work in immunotherapy and precision medicine. Her dedication to advancing oncology treatments has earned her nominations for prestigious awards, including:

Best Research Scholar Award
Excellence in Research Award
Young Scientist Award

Publications 📚

Xiaoqin has published several impactful research articles in high-ranking scientific journals. Her work has been cited widely, contributing to advancements in oncology. Some of her notable publications include:

Luo X., et al. (2023). “Advancements in Immunotherapy for HNSCC: Overcoming Drug Resistance.” Journal of Cancer Research & Therapy DOI: (Cited by 50+ articles)
Luo X., et al. (2022). “Molecular Profiling in Personalized Cancer Treatment.” Oncology Reports DOI: (Cited by 35+ articles)
Luo X., et al. (2021). “Traditional Chinese Medicine in Cancer Therapy: A Modern Perspective.” Integrative Oncology Journal DOI: (Cited by 40+ articles)

Conclusion 📊

Xiaoqin Luo is a pioneering researcher in the field of immunotherapy and oncology. Her commitment to overcoming drug resistance in HNSCC and developing personalized treatment strategies continues to shape the future of cancer research. With numerous publications, accolades, and ongoing contributions to the scientific community, she stands as a beacon of innovation in the fight against cancer.

Yinfeng Chen | Medicine | Women Researcher Award

Published on 04/02/202504/02/2025 by Forensic Scientist

Ms. Yinfeng Chen | Medicine | Women Researcher Award

Attending physician | Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University | China

Dr. Yinfeng Chen is an attending physician at the Department of Nephrology, Hangzhou TCM Hospital, affiliated with Zhejiang Chinese Medical University. With over a decade of experience in clinical nephropathy, Dr. Chen has become a recognized expert in the field. She has actively contributed to various academic endeavors and plans to further her research at the Clinical Research Institute of China-Japan Friendship Hospital in 2024. Her expertise lies in kidney diseases, and she is dedicated to providing innovative treatments to improve patient outcomes.

Profile🔍

Scopus

Strengths for the Awards

Solid Academic and Professional Background: Yinfeng holds a postgraduate degree in clinical nephropathy from Zhejiang Chinese Medicine University and has 10 years of clinical experience. This provides a solid foundation for her work in the nephrology field.
Research Contributions: She has conducted significant research on chronic kidney disease and its correlation with conditions like stroke, diabetic kidney disease, FSGS, and chronic kidney failure. Her work contributes directly to improving patient outcomes and advancing the field of nephrology.
Clinical Application and Innovation: Her commitment to providing personalized treatment plans based on individual conditions demonstrates a practical approach to her research, enhancing the impact of her findings on real-world patient care.
Active Participation in Academic Activities: She is engaged in further research at the Clinical Research Institute of China-Japan Friendship Hospital, highlighting her dedication to continuous professional development and collaboration.
Published Research: Her research has been published in reputable journals (doi: 10.1080/0886022X.2025.2452219), contributing to the academic discourse in the nephrology field.
Yinfeng Chen has demonstrated considerable strength in her clinical and research endeavors, particularly in the area of nephrology. Her dedication to improving patient care and advancing the understanding of kidney diseases makes her a strong candidate for the “Women Researcher Award.” With further contributions in publications, patents, or leadership roles in academic organizations, her profile could become even more competitive.

Education 📚

Dr. Chen graduated from Zhejiang Chinese Medicine University with a postgraduate degree in clinical nephropathy. She has since accumulated substantial clinical experience, working in the nephrology department for over 10 years. Her academic journey has continuously been complemented by active participation in academic and research activities.

Experience💼

As an attending physician in nephrology, Dr. Yinfeng Chen has developed tailored treatment plans for patients, particularly in chronic kidney disease (CKD) and diabetic kidney disease. Her decade-long clinical experience has been enriched through various collaborations, including her upcoming research at the Clinical Research Institute of China-Japan Friendship Hospital.

Research Interest On Medicine 🔬

Dr. Chen’s research interests primarily focus on kidney diseases, including chronic kidney disease, stroke, diabetic kidney disease, and FSGS (focal segmental glomerulosclerosis). She has been exploring the correlation between chronic kidney disease and stroke, among other critical issues in nephrology, with a commitment to developing innovative therapies for better patient survival and treatment outcomes.

Awards🏆

Dr. Yinfeng Chen has been nominated for the prestigious “Women Researcher Award,” a recognition of her significant contributions to nephrology and medical research. Her dedication to enhancing kidney disease treatments through her research and clinical expertise makes her an ideal candidate for this award.

Publications📖

Dr. Chen has published several studies in prominent journals. One of her recent articles, titled “Correlation Between Chronic Kidney Disease and Stroke,” was published in the International Journal of Nephrology and Renovascular Disease in 2025. The article can be accessed here. Her work is also cited by numerous other research studies.

Conclusion🌱

With a proven track record in clinical nephrology and an unwavering commitment to advancing kidney disease research, Dr. Yinfeng Chen continues to make significant strides in the field. Her upcoming work and future endeavors promise to further improve kidney disease management and treatment.

Guoying Ni | Microbiology | Best Researcher Award

Published on 04/02/202504/02/2025 by Forensic Scientist

Prof. Dr. Guoying Ni | Microbiology | Best Researcher Award

CEO | Zhongao Biomedical Technology (Guangdong) Co., Ltd | Australia

Dr. Guoying Ni is an esteemed researcher specializing in the tumor microenvironment and immunotherapy. With a PhD from Griffith University School of Medicine, Australia, Dr. Ni has dedicated nearly 15 years to groundbreaking research at the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Dr. Ni’s research has led to significant advancements, including the application of nanostructured graphene oxide for targeted immunotherapy and the discovery of tumor-inhibiting properties of Caerin peptides from Australian tree frogs.

Profile

Scopus

Strengths for the Awards

Extensive Research Experience – Dr. Ni has been engaged in tumor microenvironment and immunotherapy research for nearly 15 years across multiple institutions in Australia and China.
Innovative Contributions – Key contributions include using nanostructured graphene oxide for IL-10R antibody delivery and discovering the tumor-inhibitory effects of Caerin peptides.
High-Impact Publications – With nearly 60 research papers published in prestigious journals (Q1-ranked, impact factor over 12), Dr. Ni’s work demonstrates strong academic influence.
Funding and Grants – Dr. Ni has secured over 20 million RMB in research funding, showing recognition and support from funding bodies.

Education 🎓

Dr. Ni obtained a PhD from Griffith University School of Medicine, Australia. During this time, extensive research in immunotherapy and molecular biology laid the foundation for Dr. Ni’s expertise in cancer treatment methodologies.

Experience 🌟

Dr. Ni has held pivotal research positions at multiple prestigious institutions, including the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Key contributions include developing a novel antibody delivery system using graphene oxide nanoparticles and evaluating anti-IL-10R antibody peptides in vitro and in vivo. Additionally, Dr. Ni has over eight years of experience supervising master’s and PhD students across Australia and China.

Research Interest On Microbiology 📚

Dr. Ni’s research focuses on tumor immunotherapy, nanomedicine, and molecular oncology. Notable areas of interest include:

Graphene oxide as a targeted antibody delivery system
Anti-IL-10R therapy in cancer treatment
Caerin peptides for tumor suppression and immune response activation
Peptide-based immunotherapies for clinical applications

Awards & Honors 🏆

2022-2023: DVCR/A Launch Research Grant/Award, University of the Sunshine Coast, Australia
2016-2017: HDR Merit Research Grant, Griffith University, Australia
2013: GRPRS Scholarship and HDR Scholarship, Griffith University
Visiting Professor: Guangdong Pharmaceutical University, First People’s Hospital of Foshan, Guangdong Province

Publications 📄

Title: Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
- Authors: Fu, Q.; Luo, Y.; Li, J.; … Ni, G.; Wang, T.
- Publication Year: 2024
- Citations: 0
Title: Caerin 1.9–Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles
- Authors: Long, Y.; Duan, X.; Fu, Q.; … Liu, X.; Yang, W.
- Publication Year: 2024
- Citations: 0
Title: Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1
- Authors: Wang, Y.; Zhong, F.; Xiao, F.; … Wang, T.; Zhang, W.
- Publication Year: 2024
- Citations: 1
Title: Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
- Authors: Fu, Q.; Luo, Y.; Li, J.; … Wang, T.; Ni, G.
- Publication Year: 2024
- Citations: 0
Title: Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii
- Authors: Zhang, P.; Tang, S.; Fu, Q.; … Chen, G.; Liu, X.
- Publication Year: 2023
- Citations: 2
Title: Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
- Authors: Liu, X.; Ni, G.; Zhang, P.; … Yuan, S.; Wang, T.
- Publication Year: 2023
- Citations: 10
Title: Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
- Authors: Cavallazzi Sebold, B.; Li, J.; Ni, G.; … Liu, X.; Wang, T.
- Publication Year: 2023
- Citations: 6
Title: Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts
- Authors: He, T.; Du, J.; Zhu, K.; … Zhang, P.; Yuan, J.
- Publication Year: 2023
- Citations: 2
Title: Degradation of differently processed Mg-based implants leads to distinct foreign body reactions (FBRs) through dissimilar signaling pathways
- Authors: Liu, X.; Chen, G.; Zhong, X.; … Gao, M.; Li, H.
- Publication Year: 2023
- Citations: 5
Title: PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?

Authors: Cavallazzi Sebold, B.; Ni, G.; Li, J.; … Liu, X.; Wang, T.
Publication Year: 2023
Citations: 3

Conclusion 🎉

Dr. Guoying Ni is a trailblazer in tumor immunotherapy and nanomedicine. With numerous research contributions, multiple prestigious awards, and collaborations with globally recognized scientists, Dr. Ni continues to push the boundaries of medical research to develop innovative cancer treatments. Through dedication and expertise, Dr. Ni’s work is making a significant impact on the future of cancer immunotherapy.